← Leaderboards
Ahizechukwu C. Eke
Johns Hopkins University
$2,002,540
Attributed
$2,002,540
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $743.7K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,002,540 · 2
By mechanism
DP1$1,145,919 · 1
K23$856,621 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Eric L Nuermberger$20,859,483
- Sharon A Nachman$214,342,272
- Yuesheng Zhang$12,984,679
- Hendree E. Jones$34,132,831
- Petros C Karakousis$19,415,784
Others in their field
Other Emerging Leaders on “Pregnancy”
- Chanza Baytop · Westat, Inc.$271,217,917
- Jorge Eduardo Chavarro · Harvard School Of Public Health$13,845,291
- Tomasz Nowakowski · University Of California, San Francisco$13,203,364
- Barney Sparrow · Battelle Memorial Institu$13,048,137
- Magdalena Zernicka-Goetz · California Institute Of Technology$11,182,591
- Sara Bonamo Demauro · Children'S Hosp Of Philadelphia$11,044,839
Research focus
PregnancyTenofovirMetabolic SyndromePre-EclampsiaPreventS HealthFumaratesMetabolicPharmacologyPostpartum WomenPregnant WomenPremature BirthSafetySerumAntiretroviral TherapyCohortAdverse EffectsGestational DiabetesPerinatal HivPharmaceutical PreparationsPostpartum PeriodChildAdultTransmission Process
Grant awards (7)
Integrated proteomic and metabolomic biomarker profiling for understanding metabolic syndrome in pregnant women living with HIV on Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD)$572,794
DP1 · FY2025 · HD · contact PI
Integrated proteomic and metabolomic biomarker profiling for understanding metabolic syndrome in pregnant women living with HIV on Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD)$573,125
DP1 · FY2024 · HD · contact PI
Understanding Medication Adherence Benchmarks, Safety and Pharmacometrics of Novel Antiretrovirals in Pregnant Women Living with HIV.$170,612
K23 · FY2024 · HD · contact PI
Understanding Medication Adherence Benchmarks, Safety and Pharmacometrics of Novel Antiretrovirals in Pregnant Women Living with HIV.$171,637
K23 · FY2023 · HD · contact PI
Understanding Medication Adherence Benchmarks, Safety and Pharmacometrics of Novel Antiretrovirals in Pregnant Women Living with HIV.$171,416
K23 · FY2022 · HD · contact PI
Understanding Medication Adherence Benchmarks, Safety and Pharmacometrics of Novel Antiretrovirals in Pregnant Women Living with HIV.$171,478
K23 · FY2021 · HD · contact PI
Understanding Medication Adherence Benchmarks, Safety and Pharmacometrics of Novel Antiretrovirals in Pregnant Women Living with HIV.$171,478
K23 · FY2020 · HD · contact PI